PHC Holdings Corporation announced that it has signed a definitive agreement with Thermo Fisher Scientific to acquire Thermo Fisher’s Anatomical Pathology business for approximately $1.14B. Thermo Fisher’s Anatomical Pathology business is one of the leading providers of microscope slides, instruments and consumables in the industry and is part of Thermo Fisher’s Specialty Diagnostics Segment, operating in the US, Europe and China with approximately 1,200 employees. PHCHD currently expects to close the transaction in the second quarter of 2019, subject to customary closing conditions and the receipt of applicable regulatory approvals. Thermo Fisher expects the net dilution to 2019 adjusted earnings per share to be approximately 10c, which will be incorporated into its 2019 financial guidance that will be provided on the January 30 earnings conference call.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.